Sep 25th 2012 - Edison Investment Research today published a report on TopoTarget entitled "The Power Of BELIEF...". In summary, the report says:
The BELIEF pivotal study with Topotarget’s belinostat has met its primary endpoint with more than 20% of patients responding to treatment, causing the share price to rise 135%. Full data should be reported in Q412, which will indicate how belinostat compares to other treatments for peripheral T-cell lymphoma (PTCL) that have been approved in recent years. Topotarget remains on track to receive milestones of $10m in cash and one million Spectrum shares in H213 and for belinostat to be launched in 2014. We have increased our valuation from DKK909m to DKK1,118m.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »